TABLE 10.

Summary descriptions of medications in the pipeline for sexual dysfunctions

MEDICATION	MECHANISM OF ACTION	INDICATIONS BEING TESTED IN PHASE III	ROUTE AND DOSE	NOTES TO CLINICIANS (INCLUDING EFFECTS ON SEDATION, DEPENDENCE RISK, LIVER EFFECTS, AND OTHERS)
Dutasteride-tamsulosin (Jalyn)	Dutasteride blocks the conversion of testosterone to dihydrotestosterone (DHT), a key androgen involved in prostate gland development and growth. Tamsulosin acts as an alpha-blocker, relaxing the muscles in the bladder and prostate.114	Erectile disorder115	Oral, dutasteride 0.5mg + tamsulosin 0.4mg once daily115	The proportion of patients experiencing any adverse events, serious adverse events, and drug-related adverse events was significantly higher in the active treatment group compared to the placebo group.114
OnabotulinumtoxinA (Botox)	Blocks presynaptic release of the neurotransmitter (acetylcholine) at the neuromuscular junction116	Erectile disorder116,117	Intracavernous injection, 100 units once daily116	Mild penile pain on injection and mild penile pain for 3 days following injection were reported; no systemic effects were reported.116,117
Sildenafil oral film (CURE film Blue)	Selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase (PDE-5).118	Erectile disorder119	Oral, 25–100mg daily118	Sildenafil oral film as a high solubility, rapid onset of action, and enhanced systemic bioavailability. Mild-to-moderate headache (33.3% of subjects) and vomiting (8.3%) were reported in a healthy volunteer study.118,119